Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - July 8, 2025 607 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MIDAS study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR ESMO Asia Congress 2024, Singapore, 6-8 December November 27, 2024 Delayed irAEs Occur in a Small Subset of Patients with Melanoma,... April 1, 2021 Reunión anual de la American Society of Clinical Oncology de 2023:... June 5, 2023 Happy Nurses Month! May 3, 2021 Load more HOT NEWS Updated Nutrition Facts Label Reflects Science on Diet and Health, including... New on NCI’s Websites for September 2023 Holiday Coping and Enjoying Reunión anual de la American Society of Clinical Oncology de 2022:...
